目的 探討氫溴酸西酞普蘭片聯合丙戊酸鈉對復發(fā)雙相障礙抑郁發(fā)作患者認知功能及血清炎癥因子的影響，分析其可能作用機制。方法 選擇2014年7月-2015年12月收治的復發(fā)雙相情感障礙抑郁發(fā)作患者104例為研究對象，采用隨機數字表法分為觀察組和對照組各52例，對照組給予丙戊酸鈉治療，觀察組給予氫溴酸西酞普蘭片聯合丙戊酸鈉治療，治療8周后，比較兩組情緒狀態(tài)、認知功能、血清炎癥因子等指標。結果 治療前，兩組患者HAMD評分、BPMS評分比較無統(tǒng)計學意義；治療8周后，兩組患者的HAMD評分、BPMS評分均明顯低于同組治療前，差異有統(tǒng)計學意義（P<0.01）；且觀察組HAMD評分、BPMS評分明顯低于對照組，差異有統(tǒng)計學意義（P<0.01）。治療前，兩組患者TMT-A、TMT-B時間比較統(tǒng)計學意義；治療8周，兩組患者的TMT-A、TMT-B時間均明顯短于同組治療前，差異有統(tǒng)計學意義（P<0.05）；觀察組患者TMT-A、TMT-B時間明顯短于對照組，差異有統(tǒng)計學意義（P<0.05）。治療前，兩組患者血清中MIF、IL-1β、IL-6的含量比較無統(tǒng)計學意義；治療8周，兩組患者血清中MIF、IL-1β、IL-6的含量均明顯低于同組治療前，差異有統(tǒng)計學意義（P<0.05）；觀察組血清中MIF、IL-1β、IL-6的含量明顯低于對照組，差異有統(tǒng)計學意義（P<0.05）。結論 氫溴酸西酞普蘭片有助于緩解復發(fā)雙相障礙抑郁發(fā)作患者臨床癥狀，改善認知功能，可能與抑制血清炎癥因子表達有關。

Objective To investigate the effect of citalopram hydrobromide tablets on cognitive function and inflammatory factors in patients with recurrent bipolar disorder (BPD), and to analyze its possible mechanism of action. Methods 104 patients with recurrent BPD in our hospital from July 2014 to December 2015 were selected, and they were divided into observation group and control group by random number table, 52 cases in each group. Control group was given sodium valproate, while observation group was given citalopram hydrobromide tablets and sodium valproate. After 8-week treatment, the emotional state, cognitive function, inflammatory factors were compared between the two groups. Results Before treatment, HAMD score, BPMS score of two groups were not statistically significant. After 8 weeks of treatment, HAMD score and BPMS score of two groups were significantly lower than those in the same group before treatment (P < 0.01); and the observation group HAMD score and BPMS score were significantly lower than the control group (P < 0.01). Before treatment, TMT-A, TMT-B time of two groups were not statistically significant. After 8 weeks of treatment, TMT-A and TMT-B time of two groups were significantly shorter than the same group before treatment (P < 0.05). TMT-A TMT-B in the observation group were significantly shorter than the control group (P < 0.05). The content of serum MIF, IL-1 beta and IL-6 in two groups before treatment were not statistically significant. After 8 weeks of treatment, the contents of MIF, IL-1 beta, IL-6 in two groups were significantly lower than the same group before treatment (P < 0.05). And the levels of serum MIF, IL-1 beta, IL-6 in observation group were significantly lower than the control group (P < 0.05). Conclusion Citalopram hydrobromide tablets can relieve clinical symptoms, improve cognitive function, and it possibly has relations with inhibiting the expression of inflammatory factors.